Effects of DPP-4 inhibitor for the cognitive function of elderly patients with type 2 diabetes mellitus and Alzheimer disease
JIN Li′na1,2
1.General Department, Beijing NO.6 Hospital, Beijing 100007, China;
2.Community Health Service Management Center of Dongcheng District in Beijing City, Beijing 100007, China
Abstract：Objective To study the impact of dipeptidyl peptidase 4 (DPP-4) inhibitor Sitagliptin Phosphate on the cognitive function of elderly patients with type 2 diabetes mellitus and Alzheimer disease. Methods Eighty patients with type 2 diabetes mellitus and Alzheimer disease in Community Health Service Management Center of Dongcheng District in Beijing City from February 2016 to February 2017 were divided into two groups by random number table method, with 40 cases in each group. On basis of original therapeutic regimen, the control group was added with placebo, while the observation group was added with Sitagliptin Phosphate. The levels of blood glucose and cognitive function of the two groups were evaluated and analyzed before treatment and after treatment for 6 months. Results There were no significant differences of fasting blood glucose (FBG), glycated hemoglobin (HbA1c), and scores of mini-mental state examination (MMSE) between the two groups before treatment (P ＞ 0.05). After treatment, the FBG and HbA1c in observation group were significantly lower than those before treatment (P ＜ 0.05), the scores of MMSE were significantly higher than those before treatment (P ＜ 0.05). After treatment, the FBG and HbA1c in control group were significantly lower than those before treatment (P ＜ 0.05), while there was no statistically significant difference of MMSE scores before and after treatment (P ＞ 0.05). After treatment, the scores of MMSE in observation group were significantly higher than those of control group (P ＜ 0.05), but there were no statistically significant differences of FBG and HbA1c between the two groups (P ＞ 0.05). Conclusion DPP-4 inhibitor can significantly improve the cognitive function of elderly patients with type 2 diabetes mellitus and AD.
靳丽娜1,2. DPP-4抑制剂对老年2型糖尿病合并阿尔茨海默病患者认知功能的影响[J]. 中国医药导报, 2017, 14(35): 135-138.
JIN Li′na1,2. Effects of DPP-4 inhibitor for the cognitive function of elderly patients with type 2 diabetes mellitus and Alzheimer disease. 中国医药导报, 2017, 14(35): 135-138.
[1] 张晓洁，杨思思，张木勋，等.2型糖尿病与阿尔茨海默病互为发病风险的机制探讨[J]中国病理生理杂志，2010， 26（6）：1107-1114.
[2] Moore EM，Mander AG，Ames D，et al. Increased risk of cognitive impairment in patients with diabetes is associated with metformin [J]. Diabetes Care，2013，36（10）：2981-2987.
[3] 付剑亮，邵福源.阿尔茨海默病发病机制研究进展[J].世界临床药物，2010，31（7）：390-394.
[4] Labak M，Foniok T，Kirk D，et al. Metabolic changes in rat brain following intracerebroventricular injections of streptozotocin：a model of sporadic Alzheimer's disease [J]. Acta Neurochir Suppl，2010，106：177-181.
[5] 钱荣立.关于糖尿病的新诊断标准与分型[J].中国糖尿病杂志，2000，8（1）：5-6.
[6] American Psychiatric Association. Diagnostic and statistical manual of mental disorders（DSM-5?誖）[M]. American Psychiatric Association，2013.
[7] 彭丹涛，许贤豪，刘江红，等.简易智能精神状态检查量表检测老年期痴呆患者的应用探讨[J].中国神经免疫学和神经病学杂志，2005，12（4）：187-190.
[8] 贾建平，王荫华，张振馨，等.中国痴呆与认知障碍诊治指南（三）：神经心理评估的量表选择[J].中华医学杂志，2011，91（11）：735-741.
[9] 彭玲，张彩英，黄珊.老年糖尿病患者并发症防控认知度及其影响因素研究[J].护理实践与研究，2016，13（16）：31-32.
[10] Novak V，Milberg W，Hao Y，et al. Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes [J]. Diabetes Care，2014，37（3）：751-759.
[11] Chung CC，Pimentel D，Jor'dan AJ，et al. Inflammation-associated declines in cerebral vasoreactivity and cognition in type 2 diabetes [J]. Neurology，2015，85（5）：450-458.
[12] Ho N，Sommers MS，Lucki I. Effects of diabetes on hippocampal neurogenesis：links to cognition and depression [J]. Neurosci Biobehav Rev，2013，37（8）：1346-1362.
[13] 尚延昌，王淑辉，周波，等.老年糖尿病人群认知功能障碍的临床特征[J].临床和实验医学杂志，2014，13（23）：1935-1938.
[14] 许保磊，马丽娜，吴立壳，等.认知功能障碍对老年2型糖尿病患者生命质量的影响[J].疑难病杂志，2014，13（1）：37-39.
[15] Rizzo MR，Barbieri M，Boccardi V，et al. Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment [J]. J Gerontol A Biol Sci Med Sci，2014，69（9）：1122-1131.
[16] Pipatpiboon N，Pintana H，Pratchayasakul W，et al. DPP4-inhibitor improves neuronal insulin receptor function，brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption [J]. Eur J Pharmacol，2013，37（5）：839-849.
[17] 高欣，段春波，鲍利，等.社区老年糖尿病合并高血压患者对认知功能的影响[J].中华流行病学杂志，2014，35（7）：784-786.
[18] Tuligenga RH，Dugravot A，Tabák AG，et al. Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age：a post-hoc analysis of the Whitehall Ⅱ cohort study [J]. Lancet Diabetes Endocrinol，2014，2（3）：228-235.
[19] Khan KH，Wong M，Rihawi K，et al. Hyperglycemia and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin（PI3K/AKT/mTOR）inhibitors in phase Ⅰtrials：incidence，predictive factors，and management [J]. Oncologist，2016，21（7）：855-860.
[20] 邹小燕.社区老年糖尿病患者认知功能障碍原因及危险因素调查[J].实用预防医学，2014，21（5）：632-634.
[21] Apaijai N，Pintana H，Chattipakorn SC，et al. Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet [J]. Endocrinology，2012，153（8）：3878-3885.
[22] 范洁，张严高，王文慧，等.综合干预措施对老年糖尿病患者轻度认知功能障碍的影响[J].解放军医药杂志，2014， 26（2）：50-53.
[23] Kim C，Sohn JH，Jang MU，et al. Association between visit-to-visit glucose variability and cognitive function in aged type 2 diabetic patients：a cross-sectional study [J]. PLOS one，2015，10（7）：e0132118.
[24] Gao C，H?觟lscher C，Liu Y，et al. GSK3：a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease [J]. Rev Neurosci，2011， 23（1）：1-11.
[25] Mohan V，Yang W，Son HY，et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China，India，and Korea [J]. Diabetes Res Clin Pract，2009，83（1）：106-116.
2017, Vol. 14 
京公网安备 11010502046598号